SERTAD4: A Potential Drug Target Or Biomarker (G56256)

Target Name: SERTAD4

NCBI ID: G56256

SERTAD4

SERTAD4: A Potential Drug Target Or Biomarker

SERTAD4 (DJ667H12.2) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the superfamily of untranslated regions (SRMs), which are non-coding RNAs that play a crucial role in the regulation of gene expression. SERTAD4 has been shown to be involved in a number of important cellular processes, including cell survival, angiogenesis, and inflammation. As a result, it has generated a lot of interest as a potential drug target or biomarker.

SERTAD4 is a 21-kDa protein that is expressed in the brain, heart, and kidneys. It is composed of 129 amino acid residues and has a calculated pI of 12.2. SERTAD4 is localized to the endoplasmic reticulum (ER) and appears to be involved in the regulation of gene expression.

SERTAD4 has been shown to be involved in a number of important cellular processes. For example, SERTAD4 has been shown to be involved in the regulation of cell survival. Studies have shown that SERTAD4 can interact with the protein p53, which is a well-known tumor suppressor protein. This interaction may be important for the regulation of cell growth and division, and could potentially lead to the development of cancer.

SERTAD4 has also been shown to be involved in the regulation of angiogenesis, the process by which new blood vessels are formed. studies have shown that SERTAD4 can interact with the protein FGF1, which is a key regulator of angiogenesis. This interaction may be important for the regulation of blood vessel growth and may potentially lead to the development of diseases such as heart disease.

SERTAD4 has also been shown to be involved in the regulation of inflammation. Studies have shown that SERTAD4 can interact with the protein NF-kappa-B, which is a key regulator of inflammation. This interaction may be important for the regulation of inflammatory responses and could potentially lead to the development of diseases such as arthritis.

In addition to its involvement in cellular processes, SERTAD4 has also been shown to have potential as a drug target or biomarker. For example, SERTAD4 has been shown to be involved in the regulation of cell signaling pathways, which are important for a wide range of cellular processes. This makes it a potential target for small molecules that can modulate these signaling pathways. Additionally, SERTAD4 has been shown to have potential as a biomarker for a number of diseases, including cancer, heart disease, and neurodegenerative diseases.

Overall, SERTAD4 is a protein that has generated a lot of interest as a potential drug target or biomarker. Its involvement in cellular processes such as cell survival, angiogenesis, and inflammation makes it a promising target for small molecules that can modulate these processes. Additionally, its potential as a biomarker for a wide range of diseases makes it an important molecule to study further. Further research is needed to fully understand the role of SERTAD4 in cellular processes and its potential as a drug target or biomarker.

Protein Name: SERTA Domain Containing 4

The "SERTAD4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SERTAD4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets